OncoCyte Corporation focuses on the development and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer. The company was founded in 2009 and is based in Alameda, California. OncoCyte Corporation is a subsidiary of BioTime, Inc.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Phone(510) 775-0515
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees12
Next Earnings Date8/13/2019 (Estimated)
OptionableNot Optionable
OncoCyte (NYSEAMERICAN:OCX) Frequently Asked Questions
What is OncoCyte's stock symbol?
OncoCyte trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "OCX."
How were OncoCyte's earnings last quarter?
OncoCyte Corp (NYSEAMERICAN:OCX) released its quarterly earnings results on Tuesday, May, 14th. The biotechnology company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.01. View OncoCyte's Earnings History.
When is OncoCyte's next earnings date?
What price target have analysts set for OCX?
5 analysts have issued twelve-month price objectives for OncoCyte's shares. Their predictions range from $6.00 to $8.00. On average, they expect OncoCyte's share price to reach $7.00 in the next year. This suggests a possible upside of 47.1% from the stock's current price. View Analyst Price Targets for OncoCyte.
What is the consensus analysts' recommendation for OncoCyte?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OncoCyte in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for OncoCyte.
Has OncoCyte been receiving favorable news coverage?
Headlines about OCX stock have trended negative this week, according to InfoTrie Sentiment. The research firm ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. OncoCyte earned a media sentiment score of -2.7 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the stock's share price in the near future.
Are investors shorting OncoCyte?
OncoCyte saw a increase in short interest in the month of April. As of April 30th, there was short interest totalling 828,304 shares, an increase of 6.1% from the April 15th total of 780,426 shares. Based on an average daily volume of 126,270 shares, the days-to-cover ratio is presently 6.6 days. Approximately 2.8% of the company's stock are short sold. View OncoCyte's Current Options Chain.
Who are some of OncoCyte's key competitors?
Some companies that are related to OncoCyte include ProMetic Life Sciences (PLI), Mesoblast (MSB), Polynovo (PNV), Resverlogix (RVX), Emerald Health Therapeutics (EMH), Oxford BioMedica (OXB), Starpharma (SPL), Biotest (BIO), Neptune Wellness Solutions (NEPT), Theratechnologies (TH), Senesco Technologies (ELOX), Kodiak Sciences (KOD), IMV (IMV), Monash IVF Group (MVF) and Paradigm Biopharmaceuticals (PAR).
What other stocks do shareholders of OncoCyte own?
Who are OncoCyte's key executives?
OncoCyte's management team includes the folowing people:
- Mr. William Annett, Pres, CEO & Director (Age 65)
- Mr. Mitchell S. Levine, Chief Financial Officer
- Dr. Lyndal K. Hesterberg, Chief Scientific Officer
- Mr. Albert P. Parker II, Chief Operating Officer
- Dr. Michael D. West, Scientific Advisor, Co-CEO of Biotime,Inc. & Pres of Biotime,Inc. (Age 66)
Who are OncoCyte's major shareholders?
OncoCyte's stock is owned by many different of retail and institutional investors. Top institutional investors include Emerald Mutual Fund Advisers Trust (4.79%), Schonfeld Strategic Advisors LLC (1.67%), Renaissance Technologies LLC (0.26%), BlackRock Inc. (0.24%), Northern Trust Corp (0.11%) and JPMorgan Chase & Co. (0.09%). View Institutional Ownership Trends for OncoCyte.
Which major investors are buying OncoCyte stock?
OCX stock was purchased by a variety of institutional investors in the last quarter, including Emerald Mutual Fund Advisers Trust, Schonfeld Strategic Advisors LLC, Renaissance Technologies LLC, BlackRock Inc., JPMorgan Chase & Co., Northern Trust Corp, Spark Investment Management LLC and Virtu Financial LLC. View Insider Buying and Selling for OncoCyte.
How do I buy shares of OncoCyte?
Shares of OCX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is OncoCyte's stock price today?
One share of OCX stock can currently be purchased for approximately $4.76.
How big of a company is OncoCyte?
OncoCyte has a market capitalization of $247.39 million. OncoCyte employs 12 workers across the globe.
What is OncoCyte's official website?
How can I contact OncoCyte?
OncoCyte's mailing address is 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States. The biotechnology company can be reached via phone at (510) 775-0515.
MarketBeat Community Rating for OncoCyte (NYSEAMERICAN OCX)
MarketBeat's community ratings are surveys of what our community members think about OncoCyte and other stocks. Vote "Outperform" if you believe OCX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OCX will underperform the S&P 500 over the long term. You may vote once every thirty days.
